Related Experiment Videos
Pharmacokinetics of intramuscularly administered ertapenem
Donald G Musson1, Anup Majumdar, Kimberly Birk
1Merck Research Laboratories, West Point, Pennsylvania 19486, USA. don_musson@merck.com
Abstract:
Ertapenem (INVANZ) is a new once-a-day parental beta-lactam antimicrobial agent that has been shown to be highly effective as a single agent for treatment of various community-acquired and mixed infections. The plasma pharmacokinetics of a 1-g intramuscular (i.m.) dose was compared with those of a 1-g intravenous (i.v.) dose infused over 30 min, the recommended rate of i.v. infusion for comparison, and over 120 min, which more closely mimicked the time course for absorption of the i.m. form. In a three-period crossover study (Part A), 26 healthy subjects received single doses of ertapenem administered i.m., i.v. infused over 30 min, and i.v. infused over 120 min. Blood for ertapenem analysis was collected over 24 h postdose for each treatment. In Part B, these fasted subjects received a 1-g i.m. dose of ertapenem once daily for 7 days. Following a 1-g i.m. dose and a 1-g i.v. dose infused over 120 min, the geometric mean area under the concentration curve from hour 0 to infinity (AUC(0- infinity )) was 541.8 micro g. hr/ml following i.m. administration and 591.4 micro g. hr/ml following a 120-min infusion; the geometric mean ratio was 0.92 with a 90% confidence interval of 0.88 to 0.95. The geometric mean AUC(0- infinity ) was nearly identical when 1-g doses were infused over 30 or 120 min. Although the maximum concentration of drug in serum was somewhat lower following i.m. administration than following i.v. administration, the shape of the plasma concentration profiles was roughly comparable at later time points. Ertapenem did not accumulate after multiple 1-g i.m. daily doses over 7 days. The geometric mean ratio for AUC(0-24) (day 7/day 1) was 0.98 with a 90% confidence interval of 0.94 to 1.02. Thus, the relative bioavailability of the 1-g i.m. dose was 92%. Ertapenem does not accumulate following multiple daily 1-g i.m. doses over 7 days.
Insights
Ertapenem, a once-daily beta-lactam antimicrobial, shows 92% bioavailability via intramuscular injection compared to intravenous administration. This effective antibiotic does not accumulate with repeated daily dosing.
Area of Science:
- Pharmacology
- Infectious Diseases
- Antibiotic Therapy
Background:
- Ertapenem is a once-daily parenteral beta-lactam antimicrobial.
- It is effective as a single agent for various community-acquired and mixed infections.
Purpose of the Study:
- To compare the plasma pharmacokinetics of a 1-g intramuscular (i.m.) dose of ertapenem.
- To compare it with 1-g intravenous (i.v.) doses infused over 30 and 120 minutes.
Main Methods:
- A three-period crossover study in 26 healthy subjects.
- Single doses administered i.m., i.v. over 30 min, and i.v. over 120 min.
- Blood samples collected over 24 hours postdose for analysis.
Main Results:
- The relative bioavailability of the 1-g i.m. dose was 92% compared to the 120-min i.v. infusion.
- Area under the concentration-time curve (AUC) was comparable between i.m. and 120-min i.v. doses.
- Ertapenem did not accumulate after 7 days of once-daily 1-g i.m. dosing.
Conclusions:
- Intramuscular ertapenem provides comparable systemic exposure to intravenous administration.
- The pharmacokinetic profile supports once-daily intramuscular dosing for ertapenem.
- Ertapenem is a viable treatment option for infections requiring parenteral beta-lactam therapy.